THERAPY DOSSIER · th-5e09551e565c

Recombinant TSG-6 protein, with human mesenchymal stem/stromal cells as a parallel comparator arm

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23851308 ↗2013Mixed findings

Administration of TSG-6 improves memory after traumatic brain injury in mice.

MouseTBIControlled cortical impactC57BL/6jMaleIntravenous, tail veinTSG-6 50 microgram per mouse in 200 microlitre PBS; 10 and…6 hours after controlled cortical impact, with a second dose in some mice at 24…

Model: Controlled cortical impact via 4 mm craniectomy over right temporo-parietal cortex; single impact of 0.8 mm deformation depth, 4.5 m/s velocity, 250 ms dwell, 3 mm impactor tip; sham was craniectomy without impact

Intravenous TSG-6 during the early inflammatory phase reduced neutrophil infiltration and MMP9 activity at 24 h, reduced blood brain barrier leakage at day 3 and cut hemisphere lesion volume by about 40 per cent. It also improved spatial learning, working memory, depressive-like behaviour and newbo…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…